Please ensure Javascript is enabled for purposes of website accessibility

Why Autolus Therapeutics Stock Skyrocketed Today

By Keith Speights - May 12, 2021 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.

What happened

Shares of Autolus Therapeutics (AUTL -6.96%) were trading 35% higher as of 3:37 p.m. EDT on Wednesday. Those big gains came after the company announced that its experimental CD19 cell therapy, AUTO1, had achieved 100% remission in patients with relapsed/refractory indolent non-Hodgkin lymphoma in an early-stage study.

So what

Autolus stated that AUTO1's results will be included in an abstract presentation at the European Hematology Association (EHA) Virtual Congress scheduled for June 9 through June 17. The company said that of the 10 patients who had received AUTO1 as of Feb. 18, nine were evaluable. All nine of those patients achieved complete remission rates.

Scientist looking through a microscope

Image source: Getty Images.

The company also noted that no incidents of high-grade cytokine release syndrome (CRS) or neurotoxicity were observed in any of the patients. CRS is often observed in patients who receive chimeric antigen receptor T cell (CAR-T) therapies. However, grade 1 (mild) CRS occurred in four patients, and one experienced grade 2 (moderate) CRS. In addition, one patient who achieved complete remission from their lymphoma died from COVID-19.

Now what

The next major catalyst for the clinical-stage biotech stock shouldn't be far off. Autolus expects to report results from a phase 1 study evaluating programmed T cell therapy AUTO4 in treating peripheral T cell lymphoma in the second half of this year. The company also hopes to announce results from a potentially pivotal study of AUTO1 in treating relapsed/refractory B-acute lymphocytic leukemia in 2022. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Autolus Therapeutics plc Stock Quote
Autolus Therapeutics plc
$3.34 (-6.96%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.